The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Effects of Abaloparatide, a Human Parathyroid Hormone-Related Peptide Analog, on Bone Mineral Density in Postmenopausal Women with Osteoporosis
Abstract
CONTEXT: Abaloparatide is a novel synthetic peptide analog of parathyroid hormone-related protein (PTHrP) that is currently being developed as a potential anabolic agent in the treatment of postmenopausal osteoporosis. OBJECTIVE: This study sought to assess the effects of abaloparatide on bone mineral density (BMD) at the lumbar spine, total hip, and femoral neck in postmenopausal women with osteoporosis. DESIGN: Multi-center, multi-national, double-blind placebo controlled trial in which postmenopausal women were randomly assigned to receive 24 weeks of treatment with daily sc injections of placebo, abaloparatide, 20, 40, or 80 μg, or teriparatide, 20 μg. A 24-week extension was also performed in a subset of subjects. PARTICIPANTS: Postmenopausal women with osteoporosis (n = 222). MAIN OUTCOME MEASURES: BMD by dual-x-ray absorptiometry and biochemical markers of bone turnover. RESULTS: At 24 weeks, lumbar spine BMD increased by 2.9, 5.2, and 6.7% in the abaloparatide, 20-, 40-, and 80-μg groups, respectively, and 5.5% in the teriparatide group. The increases in the 40- and 80-μg abaloparatide groups and the teriparatide group were significantly greater than placebo (1.6%). Femoral neck BMD increased by 2.7, 2.2, and 3.1% in abaloparatide, 20-, 40-, and 80-μg groups, respectively, and 1.1% in the teriparatide group. The increase in femoral neck BMD with abaloparatide, 80 μg was significantly greater than placebo (0.8%). Total hip BMD increased by 1.4, 2.0, and 2.6% in the abaloparatide, 20-, 40-, and 80-μg groups, respectively. The total hip increases in the 40- and 80-μg abaloparatide groups were greater than both placebo (0.4%) and teriparatide (0.5%). CONCLUSIONS: Compared with placebo, 24 weeks of daily sc abaloparatide increases BMD of the lumbar spine, femoral neck, and total hip in a dose-dependent fashion. Moreover, the abaloparatide-induced BMD increases at the total hip are greater than with the marketed dose of teriparatide. These results support the further investigation of abaloparatide as an anabolic therapy in postmenopausal osteoporosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Self-citationMacLean, C., Newberry, S., Maglione, M., McMahon, M., Ranganath, V., Suttorp, M., Mojica, W., Timmer, M., Alexander, A., McNamara, M., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-3-200802050-00198 · Cited by 529
PTHrP and Skeletal Development
KRONENBERG, H. M. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1346.002 · Cited by 429
Miller, P. D., Mcclung, M. R., Macovei, L., Stakkestad, J. A., Luckey, M., Bonvoisin, B., Reginster, J.-Y., Recker, R. R., Hughes, C., Lewiecki, E. M., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050313 · Cited by 333
Hochberg, M. C., Ross, P. D., Black, D., Cummings, S. R., Genant, H. K., Nevitt, M. C., Barrett-Connor, E., Musliner, T., Thompson, D., & for the Fracture Intervention Trial Research Group (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199906)42:6<1246::aid-anr22>3.0.co;2-u · Cited by 287
Leder, B. Z., Tsai, J. N., Uihlein, A. V., Burnett-Bowie, S.-A. M., Zhu, Y., Foley, K., Lee, H., & Neer, R. M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4440 · Cited by 282
Self-citationImportance of Precision in Bone Density Measurements
Bonnick, S. L., Johnston, C. C., Kleerekoper, M., Lindsay, R., Miller, P., Sherwood, L., & Siris, E. (2001) · Journal of Clinical Densitometry · doi:10.1385/jcd:4:2:105 · Cited by 277
Dean, T., Vilardaga, J.-P., Potts, J. T., & Gardella, T. J. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0274 · Cited by 227
Okazaki, M., Ferrandon, S., Vilardaga, J.-P., Bouxsein, M. L., Potts, J. T., & Gardella, T. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808750105 · Cited by 167
Hansen, S., Hauge, E., Jensen, J. B., & Brixen, K. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1784 · Cited by 152
Tsai, J. N., Uihlein, A. V., Burnett‐Bowie, S. M., Neer, R. M., Zhu, Y., Derrico, N. P., Lee, H., Bouxsein, M., & Leder, B. Z. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2315 · Cited by 149
Self-citationPioszak, A. A., Parker, N. R., Gardella, T. J., & Xu, H. E. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.022905 · Cited by 147
Bonnick, S. L., Saag, K. G., Kiel, D. P., McClung, M. R., Hochberg, M. C., Burnett‐Bowie, S. M., Sebba, A. I., Kagan, R., Chen, E., Thompson, D. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2602 · Cited by 145
Recker, R. R., Marín, F., Ish‐Shalom, S., Moericke, R., Hawkins, F. G., Kapetanos, G., de la Peña, M. P., Kekow, J., Farrerons, J., Sanz, B., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090315 · Cited by 121
Femoral strength in osteoporotic women treated with teriparatide or alendronate
Keaveny, T. M., McClung, M. R., Wan, X., Kopperdahl, D. L., Mitlak, B., & Krohn, K. (2011) · Bone · doi:10.1016/j.bone.2011.10.002 · Cited by 99
Horwitz, M. J., Tedesco, M. B., García-Ocaña, A., Sereika, S. M., Prebehalla, L., Bisello, A., Hollis, B. W., Gundberg, C. M., & Stewart, A. F. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0233 · Cited by 94
Ma, Y. L., Zeng, Q. Q., Chiang, A. Y., Burr, D. B., Li, J., Dobnig, H., Fahrleitner‐Pammer, A., Michalská, D., Marín, F., Pavo, I. J., et al. (2013) · Bone · doi:10.1016/j.bone.2013.11.011 · Cited by 90
Dempster, D. W., Zhou, H., Recker, R. R., Brown, J. P., Bolognese, M. A., Recknor, C. P., Kendler, D. L., Lewiecki, E. M., Hanley, D. A., Rao, D. S., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1262 · Cited by 80
Han, S.-L., & Wan, S.-L. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02837.x · Cited by 77
Horwitz, M. J., Augustine, M., Kahn, L., Martin, E. A., Oakley, C. C., Carneiro, R. M., Tedesco, M. B., Laslavic, A., Sereika, S. M., Bisello, A., et al. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1978 · Cited by 67
Sebba, A. I., Bonnick, S. L., Kagan, R., Thompson, D. E., Skalky, C. S., Chen, E., & de Papp, A. E. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904x16768 · Cited by 62
Nishiyama, K. K., Cohen, A., Young, P., Wang, J., Lappe, J. M., Guo, X.-D. E., Dempster, D. W., Recker, R. R., & Shane, E. J. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1041 · Cited by 60
Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis
Gallagher, J. C., Rosen, C. J., Chen, P., Misurski, D. A., & Marcus, R. (2006) · Bone · doi:10.1016/j.bone.2006.06.007 · Cited by 56
Use of bisphosphonates in the management of postmenopausal osteoporosis
Papapoulos, S. E. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05767.x · Cited by 48
Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment
Sebba, A. I. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.03.008 · Cited by 47
Horwitz, M. J., Tedesco, M. B., Sereika, S. M., García-Ocaña, A., Bisello, A., Hollis, B. W., Gundberg, C. M., & Stewart, A. F. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1976-3 · Cited by 42
Parathyroid hormone treatment for osteoporosis
Cosman, F. (2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32831a46d6 · Cited by 41
Ma, Y. L., Marín, F., Stepan, J. J., Ish‐Shalom, S., Moericke, R., Hawkins, F. G., Kapetanos, G., de la Peña, M. P., Kekow, J., Martínez, G., et al. (2011) · Bone · doi:10.1016/j.bone.2011.01.012 · Cited by 29
Cited by
Osteoporosis treatment: recent developments and ongoing challenges
Khosla, S., & Hofbauer, L. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30188-2 · Cited by 1,019
Eastell, R., O'Neill, T. W., Hofbauer, L. C., Langdahl, B., Reid, I. R., Gold, D. T., & Cummings, S. R. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.69 · Cited by 827
G protein-coupled receptors: structure- and function-based drug discovery
Yang, D., Zhou, Q., Labroska, V., Qin, S., Darbalaei, S., Wu, Y., Yuliantie, E., Xie, L., Tao, H., Cheng, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00435-w · Cited by 632
Physiological Bone Remodeling: Systemic Regulation and Growth Factor Involvement
Siddiqui, J. A., & Partridge, N. C. (2016) · Physiology · doi:10.1152/physiol.00061.2014 · Cited by 534
Hattersley, G., Dean, T., Corbin, B. A., Bahar, H., & Gardella, T. J. (2016) · Endocrinology · doi:10.1210/en.2015-1726 · Cited by 300
Self-citation
Metadata
- Authors
- Leder, B. Z., O'Dea, L. S. L., Zanchetta, J. R., Kumar, P., Banks, K., McKay, K., Lyttle, C. R., & Hattersley, G.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-02
- Volume
- 100
- Issue
- 2
- Pages
- 697-706
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2159816244
- Cited by
- 261
- References
- 28
- FWCI
- 19.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.